Crinetics(CRNX.US)盘初暴涨23% FDA批准其生长激素紊乱治疗方案

Core Viewpoint - Crinetics (CRNX.US) shares surged 23% to a new 8-month high of $44.30 following FDA approval of its drug for acromegaly, a rare disease caused by excess growth hormone production [1] Company Summary - The approved drug, named Palsonify, is an oral treatment taken once daily [1] - The company anticipates the drug will be available in the U.S. market by early October [1] - The FDA approval was based on data from two Phase 3 trials, which demonstrated good drug tolerability and provided rapid and consistent biochemical control along with symptom relief [1]